The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about ...

Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research ...

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...